A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury

Science of the Total Environment

Volumn 408, Issue 19, 2010, Pages 4085-4092

  Jacob Ferreira, Anna L B ^a   Passos, Carlos J S ^b   Gerlach, Raquel F ^c   Barbosa, Fernando ^c   Tanus Santos, Jose E ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Matrix metalloproteinases; Mercury; Polymorphism

Indexed keywords

ACTIVITY LEVELS; CARDIO-VASCULAR DISEASE; ENDOGENOUS INHIBITOR; FUNCTIONAL MATRIX; GELATIN ZYMOGRAPHY; GENETIC POLYMORPHISMS; HG CONCENTRATIONS; LOW LEVEL; MATRIX METALLOPROTEINASES; METALLOPROTEINASES; MICRO SATELLITE; PLASMA SAMPLES; PROMOTER REGION; TISSUE INHIBITOR;

BLOOD VESSELS; CONCENTRATION (PROCESS); ELECTROMAGNETIC INDUCTION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ENCODING; GENE EXPRESSION; HEALTH RISKS; INDUCTIVELY COUPLED PLASMA; INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY; POLYMORPHISM;

MERCURY (METAL);

GELATINASE B; MERCURY; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

BLOOD; CONCENTRATION (COMPOSITION); ENZYME ACTIVITY; FUNCTIONAL RESPONSE; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; INDUCTIVELY COUPLED PLASMA METHOD; INHIBITOR; MERCURY (ELEMENT); PLASMA; POLLUTION EFFECT; POLLUTION EXPOSURE; TOXICITY TEST;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MASS SPECTROMETRY; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; ZYMOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MERCURY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 77954624491     PISSN: 00489697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2010.05.036     Document Type: Article

References (68)

1. Altieri P., Brunelli C., Garibaldi S., Nicolino A., Ubaldi S., Spallarossa P., et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003, 33:648-656.
2. Barbosa F., Gerlach R.F., Tanus-Santos J.E. Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations. Basic Clin Pharmacol Toxicol 2006, 98:559-564.
3. Belo V.A., Souza-Costa D.C., Lana C.M., Caputo F.L., Marcaccini A.M., Gerlach R.F., et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 2009, 42:984-990.
4. Belvisi M.G., Bottomley K.M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?. Inflamm Res 2003, 52:95-100.
5. Berglund M., Lind B., Bjornberg K.A., Palm B., Einarsson O., Vahter M. Inter-individual variations of human mercury exposure biomarkers: a cross-sectional assessment. Environ Health 2005, 4:20.
6. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
7. Boffetta P., Sallsten G., Garcia-Gomez M., Pompe-Kirn V., Zaridze D., Bulbulyan M., et al. Mortality from cardiovascular diseases and exposure to inorganic mercury. Occup Environ Med 2001, 58:461-466.
8. Bonnema D.D., Webb C.S., Pennington W.R., Stroud R.E., Leonardi A.E., Clark L.L., et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 2007, 13:530-540.
9. Budtz-Jorgensen E., Grandjean P., Jorgensen P.J., Weihe P., Keiding N. Association between mercury concentrations in blood and hair in methylmercury-exposed subjects at different ages. Environ Res 2004, 95:385-393.
10. Castro M.M., Rizzi E., Figueiredo-Lopes L., Fernandes K., Bendhack L.M., Pitol D.L., et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008, 198:320-331.
11. Castro M.M., Rizzi E., Prado C.M., Rossi M.A., Tanus-Santos J.E., Gerlach R.F. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010, 29:194-201.
12. Clarkson T.W., Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol 2006, 36:609-662.
13. de Marco K.C., Passos C.J., Sertorio J., Tanus-Santos J.E., Barbosa F. Environmental exposure to methylmercury is associated with a decrease in nitric oxide production. Basic Clin Pharmacol Toxicol 2009, 106(5):411-415.
14. Demacq C., de Souza A.P., Machado A.A., Gerlach R.F., Tanus-Santos J.E. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2006, 365:183-187.
15. Demacq C., Metzger I.F., Gerlach R.F., Tanus-Santos J.E. Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers. Clin Chim Acta 2008, 394:72-76.
16. Demacq C., Vasconcellos V.B., Marcaccini A.M., Gerlach R.F., Silva W.A., Tanus-Santos J.E. Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 2008, 46:57-63.
17. Demacq C., Vasconcellos V.B., Marcaccini A.M., Gerlach R.F., Machado A.A., Tanus-Santos J.E. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J 2009, 9:265-273.
18. Fiotti N., Altamura N., Fisicaro M., Carraro N., Adovasio R., Sarra V.M., et al. MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis 2005, 182:287-292.
19. Fiotti N., Altamura N., Fisicaro M., Carraro N., Uxa L., Grassi G., et al. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:1330-1336.
20. Garvin P., Nilsson L., Carstensen J., Jonasson L., Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS One 2008, 3:e1774.
21. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005, 344:147-149.
22. Gerlach R.F., Demacq C., Jung K., Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007, 40:119-123.
23. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992, 267:4583-4591.
24. Goncalves F.M., Jacob-Ferreira A.L., Gomes V.A., Casella-Filho A., Chagas A.C., Marcaccini A.M., et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009, 403:173-177.
25. Goulle J.P., Mahieu L., Castermant J., Neveu N., Bonneau L., Laine G., et al. Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair. Reference values. Forensic Sci Int 2005, 153:39-44.
26. Guallar E., Sanz-Gallardo M.I., van't Veer P., Bode P., Aro A., Gomez-Aracena J., et al. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 2002, 347:1747-1754.
27. Jacob-Ferreira A.L., Passos C.J., Jordao A.A., Fillion M., Mergler D., Lemire M., et al. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities. Basic Clin Pharmacol Toxicol 2009, 105:281-288.
28. Jones G.T., Phillips V.L., Harris E.L., Rossaak J.I., van Rij A.M. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J Vasc Surg 2003, 38:1363-1367.
29. Koh Y.S., Chang K., Kim P.J., Seung K.B., Baek S.H., Shin W.S., et al. A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. Int J Cardiol 2008, 127:430-432.
30. Lamblin N., Bauters C., Hermant X., Lablanche J.M., Helbecque N., Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 2002, 40:43-48.
31. Lynch J.R., Blessing R., White W.D., Grocott H.P., Newman M.F., Laskowitz D.T. Novel diagnostic test for acute stroke. Stroke 2004, 35:57-63.
32. Maeda S., Haneda M., Guo B., Koya D., Hayashi K., Sugimoto T., et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int 2001, 60:1428-1434.
33. Marcaccini A.M., Novaes A.B., Meschiari C.A., Souza S.L., Palioto D.B., Sorgi C.A., et al. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy. Clin Chim Acta 2009, 409:117-122.
34. Martinez M.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B., Gerlach R.F., et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006, 47:117-122.
35. Martins-Oliveira A., Speciali J.G., Dach F., Marcaccini A.M., Goncalves F.M., Gerlach R.F., et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta 2009, 408:60-64.
36. Mergler D., Anderson H.A., Chan L.H., Mahaffey K.R., Murray M., Sakamoto M., et al. Methylmercury exposure and health effects in humans: a worldwide concern. Ambio 2007, 36:3-11.
37. Morgan A.R., Zhang B., Tapper W., Collins A., Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med 2003, 81:321-326.
38. Morimoto Y., Tsuda T., Nakamura H., Hori H., Yamato H., Nagata N., et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and extracellular matrix mRNA following exposure to mineral fibers and cigarette smoke in vivo. Environ Health Perspect 1997, 105(Suppl. 5):1247-1251.
39. Ning W., Dong Y., Sun J., Li C., Matthay M.A., Feghali-Bostwick C.A., et al. Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts. Am J Respir Cell Mol Biol 2007, 36:480-490.
40. Paczek L., Michalska W., Bartlomiejczyk I. Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process. Age Ageing 2008, 37:318-323.
41. Palei A.C., Sandrim V.C., Cavalli R.C., Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008, 41:875-880.
42. Palei A.C., Sandrim V.C., Duarte G., Cavalli R.C., Gerlach R.F., Tanus-Santos J.E. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta 2010, 411:874-877.
43. Palmer C.D., Lewis M.E., Geraghty C.M., Barbosa F., Parsons P.J. Determination of lead, cadmium and mercury in blood for assessment of environmental exposure: a comparison between inductively coupled plasma-mass spectrometry and atomic absorption spectrometry. Spectrochim Acta Part B At Spectrosc 2006, 61:980-990.
44. Passos C.J., Mergler D. Human mercury exposure and adverse health effects in the Amazon: a review. Cad Saude Publica 2008, 24(Suppl. 4):s503-s520.
45. Passos C.J., Da Silva D.S., Lemire M., Fillion M., Guimaraes J.R., Lucotte M., et al. Daily mercury intake in fish-eating populations in the Brazilian Amazon. J Expo Sci Environ Epidemiol 2008, 18:76-87.
46. Peters D.G., Kassam A., St Jean P.L., Yonas H., Ferrell R.E. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999, 30:2612-2616.
47. Pollanen P.J., Karhunen P.J., Mikkelsson J., Laippala P., Perola M., Penttila A., et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol 2001, 21:1446-1450.
48. Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007, 26:587-596.
49. Raitio A., Tuomas H., Kokkonen N., Salo T., Sorsa T., Hanemaaijer R., et al. Levels of matrix metalloproteinase-2, -9 and -8 in the skin, serum and saliva of smokers and non-smokers. Arch Dermatol Res 2005, 297:242-248.
50. Registry AfTSaD. Toxicological Profile for Mercury. In: Service USDoHaHSPH, editor, Atlanta, GA, 1999.
51. Salonen J.T., Seppanen K., Lakka T.A., Salonen R., Kaplan G.A. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 2000, 148:265-273.
52. Samnegard A., Hulthe J., Silveira A., Ericsson C.G., Hamsten A., Eriksson P. Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. Atherosclerosis 2009, 202:550-556.
53. Sandrim V.C., Palei A.C., Luizon M.R., Izidoro-Toledo T.C., Cavalli R.C., Tanus-Santos J.E. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 2010, 10:40-45.
54. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology 1992, 24:104-108.
55. Segura-Valdez L., Pardo A., Gaxiola M., Uhal B.D., Becerril C., Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000, 117:684-694.
56. Shimajiri S., Arima N., Tanimoto A., Murata Y., Hamada T., Wang K.Y., et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999, 455:70-74.
57. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005, 38:410-414.
58. Sundstrom J., Vasan R.S. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006, 17:45-53.
59. Tan J., Hua Q., Xing X., Wen J., Liu R., Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007, 30:959-963.
60. Timms P.M., Mannan N., Hitman G.A., Noonan K., Mills P.G., Syndercombe-Court D., et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?. QJM 2002, 95:787-796.
61. Uzuelli J.A., Dias-Junior C.A., Tanus-Santos J.E. Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. Clin Chim Acta 2008, 388:184-188.
62. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002, 37:375-536.
63. Virtanen J.K., Voutilainen S., Rissanen T.H., Mursu J., Tuomainen T.P., Korhonen M.J., et al. Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in eastern Finland. Arterioscler Thromb Vasc Biol 2005, 25:228-233.
64. Virtanen J.K., Rissanen T.H., Voutilainen S., Tuomainen T.P. Mercury as a risk factor for cardiovascular diseases. J Nutr Biochem 2007, 18:75-85.
65. Woessner J.F. The matrix metalloproteinase family. Matrix Metalloproteinases 1998, 1-14. Academic Press, San Diego, CA. W.C. Parks, R.P. Mecham (Eds.).
66. Wright J.L., Tai H., Wang R., Wang X., Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling. Am J Physiol Lung Cell Mol Physiol 2007, 292:L125-L133.
67. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
68. Zouridakis E., Avanzas P., Arroyo-Espliguero R., Fredericks S., Kaski J.C. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004, 110:1747-1753.